- Home
- KRON vs ELTX Comparison
KRON vs ELTX Comparison
Compare KRON & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- ELTX
- Stock Information
- Founded
- KRON 2017
- ELTX 2011
- Country
- KRON United States
- ELTX United States
- Employees
- KRON 8
- ELTX N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- KRON Health Care
- ELTX Health Care
- Exchange
- KRON Nasdaq
- ELTX Nasdaq
- Market Cap
- KRON 54.1M
- ELTX 121.7M
- IPO Year
- KRON 2020
- ELTX N/A
- Fundamental
- Price
- KRON $0.88
- ELTX $7.72
- Analyst Decision
- KRON Buy
- ELTX Strong Buy
- Analyst Count
- KRON 3
- ELTX 2
- Target Price
- KRON $1.63
- ELTX $9.50
- AVG Volume (30 Days)
- KRON 1.4M
- ELTX 57.8K
- Earning Date
- KRON 08-07-2025
- ELTX 08-12-2025
- Dividend Yield
- KRON N/A
- ELTX N/A
- EPS Growth
- KRON N/A
- ELTX N/A
- EPS
- KRON N/A
- ELTX N/A
- Revenue
- KRON $9,192,000.00
- ELTX N/A
- Revenue This Year
- KRON N/A
- ELTX N/A
- Revenue Next Year
- KRON N/A
- ELTX N/A
- P/E Ratio
- KRON N/A
- ELTX N/A
- Revenue Growth
- KRON 21.16
- ELTX N/A
- 52 Week Low
- KRON $0.65
- ELTX $3.34
- 52 Week High
- KRON $1.60
- ELTX $9.99
- Technical
- Relative Strength Index (RSI)
- KRON 65.76
- ELTX 55.57
- Support Level
- KRON $0.87
- ELTX $7.70
- Resistance Level
- KRON $0.90
- ELTX $8.19
- Average True Range (ATR)
- KRON 0.02
- ELTX 0.36
- MACD
- KRON 0.00
- ELTX -0.09
- Stochastic Oscillator
- KRON 53.86
- ELTX 19.05
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.